These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33169802)

  • 1. Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.
    Heron CE; Ghamrawi RI; Balogh EA; Feldman SR
    Am J Clin Dermatol; 2021 Mar; 22(2):221-231. PubMed ID: 33169802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 4. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
    Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
    Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab.
    Aarebrot AK; Solberg SM; Davies R; Bader LI; Holmes TD; Gavasso S; Bryceson YT; Jonsson R; Sandvik LF; Appel S
    Br J Dermatol; 2018 Aug; 179(2):371-380. PubMed ID: 29274242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.
    Jullien D; Prinz JC; Nestle FO
    J Invest Dermatol; 2015 Jan; 135(1):31-38. PubMed ID: 25120005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
    Bagel J; Lebwohl M; Israel RJ; Jacobson A
    J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
    Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 18. Considerations related to comparative clinical studies for biosimilars.
    Rathore AS; Stevenson JG; Chhabra H
    Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.